Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 5,305 matching trials from the live ClinicalTrials.gov search.

Filters: Louisville, Kentucky Clear all

Conditions: Elevated Intraocular Pressure
Interventions: Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%; Drug
Lead sponsor: TearClear Corp; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 20
States / cities: Garden Grove, California • Glendale, California • Mission Hills, California + 16 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 955
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 654 more

Conditions: Super-Refractory Status Epilepticus
Interventions: SAGE-547, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 100
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 76 more

Conditions: Non-Small Cell Lung Cancer
Interventions: ASA404, Placebo, carboplatin, Paclitaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 100
States / cities: Mobile, Alabama • Tucson, Arizona • Bentonville, Arkansas + 86 more

Conditions: Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Interventions: Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 21 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 152
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more

Conditions: Ovarian Cancer
Interventions: NovoTTF-100L(O), Paclitaxel; Device · Drug
Lead sponsor: NovoCure Ltd.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 59
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more

Conditions: Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Interventions: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 365 Days
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 116
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more

Conditions: Spinal Deformity
Interventions: Not listed
Lead sponsor: Shay Bess; Other
Eligibility: 40 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Sacramento, California • San Francisco, California • Denver, Colorado + 6 more

Conditions: Scalp Psoriasis
Interventions: Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo; Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 31
States / cities: Encinitas, California • Fremont, California • San Diego, California + 25 more

Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions: Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Multigated Acquisition Scan, Positron Emission Tomography, Trametinib Dimethyl Sulfoxide; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 752
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 464 more

Conditions: Weight Loss
Interventions: VK2735; Drug
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 135
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 119 more

Conditions: Endometrial Cancer
Interventions: Lifileucel; Biological
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 9 more

Conditions: Ovarian Cancer
Interventions: carboplatin, paclitaxel; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 144
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 112 more

Conditions: Spinal Cord Injury
Interventions: Riluzole; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 7
States / cities: Miami, Florida • Louisville, Kentucky • Baltimore, Maryland + 3 more

Conditions: Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
Interventions: Bone Marrow Biopsy, Epoetin Alfa, Laboratory Biomarker Analysis, Lenalidomide; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 507
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 345 more

Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Interventions: Device; Device
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1983 – 2040
U.S. locations: 114
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 111 more

Conditions: Osteoarthritis, Post-traumatic; Arthrosis
Interventions: Sidus Stem-Free Shoulder; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Louisville, Kentucky • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Dry Eye Disease
Interventions: OK-101, Placebo; Drug
Lead sponsor: Okyo Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 6
States / cities: Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more

Conditions: Epilepsy, Complex Partial
Interventions: Zonisamide; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 25
States / cities: Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 22 more

Conditions: Hemophilia B
Interventions: rFIXFc; Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Up to 17 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 11
States / cities: Sacramento, California • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more

Conditions: Limited Stage Small Cell Lung Cancer
Interventions: BMS-986489, Durvalumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 34
States / cities: Daphne, Alabama • Santa Barbara, California • Fort Myers, Florida + 30 more

Conditions: Myelodysplastic Syndrome, Anemia
Interventions: Elritercept, Epoetin Alfa; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 31
States / cities: Gilbert, Arizona • Duarte, California • Santa Rosa, California + 26 more

Conditions: Cholangiocarcinoma
Interventions: Fimaporfin and Gemcitabine, Gemcitabine/Cisplatin chemotherapy; Drug
Lead sponsor: PCI Biotech AS; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Duarte, California • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions: Dexpramipexole Dihydrochloride, Placebo; Drug
Lead sponsor: Areteia Therapeutics; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 76
States / cities: Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 64 more

Search by objective public record fields.

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

A Study With SAGE-547 for Super-Refractory Status Epilepticus

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Cost Effectiveness of Nonoperative Management for Adult Spinal Deformity

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

VK2735 for Weight Management Phase 3

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer

Safety of Riluzole in Patients With Acute Spinal Cord Injury

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

Long Term Sidus PMCF

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)